Colorectal Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Colorectal Cancer, including details on symptoms, genetics, screening, treatment, information.

Volume 5 (2008), Issue 3 (March)

1. Rectovaginal examinations and human papillomavirus: can we decrease the risk of colorectal infection?
   Am J Obstet Gynecol, 198(3): 260.e1-2. [Abstract] [Full-text]
2. Synergistic antitumor activity of the novel SN-38-incorporating polymeric micelles, NK012, combined with 5-fluorouracil in a mouse model of colorectal cancer, as compared with that of irinotecan plus 5-fluorouracil.
   Int J Cancer, 122(9): 2148-53. [Abstract] [Full-text]
3. Rectal gastrointestinal stromal tumors associated with a novel germline KIT mutation.
   Int J Cancer, 122(9): 2160-4. [Abstract] [Full-text]
4. Diagnostic targeting of colon cancer using a novel fluorescent somatostatin conjugate in a mouse xenograft model.
   Int J Cancer, 122(9): 2044-9. [Abstract] [Full-text]
5. Apoptosis of estrogen-receptor negative breast cancer and colon cancer cell lines by PTP alpha and src RNAi.
   Int J Cancer, 122(9): 1999-2007. [Abstract] [Full-text]
6. The possible role of factor H in colon cancer resistance to complement attack.
   Int J Cancer, 122(9): 2030-7. [Abstract] [Full-text]
7. Combination of atorvastatin and celecoxib synergistically induces cell cycle arrest and apoptosis in colon cancer cells.
   Int J Cancer, 122(9): 2115-24. [Abstract] [Full-text]
8. Plasma vitamin B12 concentrations and the risk of colorectal cancer: a nested case-referent study.
   Int J Cancer, 122(9): 2057-61. [Abstract] [Full-text]
9. Quantification of risk of a positive (R1) resection margin following hepatic resection for metastatic colorectal cancer: an aid to clinical decision-making.
   Surg Oncol, 17(1): 3-13. [Abstract] [Full-text]
10. The Quality Initiative in Rectal Cancer (QIRC) trial: study protocol of a cluster randomized controlled trial in surgery.
    BMC Surg, 8: 4. [Abstract] [Full-text]
11. Growth inhibition of insulin-like growth factor I receptor monoclonal antibody to human colorectal cancer cells.
    Cancer Invest, 26(3): 230-6. [Abstract] [Full-text]
12. Chromosomal breakpoints in primary colon cancer cluster at sites of structural variants in the genome.
    Cancer Res, 68(5): 1284-95. [Abstract] [Full-text]
13. Interobserver agreement in grading of colorectal cancers-findings from a nationwide web-based survey of histopathologists.
    Histopathology, 52(4): 494-9. [Abstract] [Full-text]
14. Health-protective and adverse effects of the apolipoprotein E epsilon2 allele in older men.
    J Am Geriatr Soc, 56(3): 478-83. [Abstract] [Full-text]
15. In vivo confocal laser scanning chromo-endomicroscopy of colorectal neoplasia: changing the technological paradigm.
    Histopathology, 52(4): 417-26. [Abstract] [Full-text]
16. Prevalence of nonpolypoid (flat and depressed) colorectal neoplasms in asymptomatic and symptomatic adults.
    JAMA, 299(9): 1027-35. [Abstract] [Full-text]
17. Identification of susceptibility genes for cancer in a genome-wide scan: results from the colon neoplasia sibling study.
    Am J Hum Genet, 82(3): 723-36. [Abstract] [Full-text]
18. Visceral obesity as a risk factor for colorectal neoplasm.
    J Gastroenterol Hepatol, 23(3): 411-7. [Abstract] [Full-text]
19. Differences between right- and left-sided colon cancer in patient characteristics, cancer morphology and histology.
    J Gastroenterol Hepatol, 23(3): 418-23. [Abstract] [Full-text]
20. High folic acid increases cell turnover and lowers differentiation and iron content in human HT29 colon cancer cells.
    Br J Nutr, 99(4): 703-8. [Abstract] [Full-text]
21. Downregulation of tumor suppressor Pdcd4 promotes invasion and activates both beta-catenin/Tcf and AP-1-dependent transcription in colon carcinoma cells.
    Oncogene, 27(11): 1527-35. [Abstract] [Full-text]
22. Quality of life and symptom attribution in long-term colon cancer survivors.
    J Eval Clin Pract, 14(2): 254-8. [Abstract] [Full-text]
23. Lynch syndrome: still not a familiar picture.
    World J Surg Oncol, 6: 21. [Abstract] [Full-text]
24. Management of early rectal cancer.
    Br J Surg, 95(4): 409-23. [Abstract] [Full-text]
25. Proteasomal degradation of Atoh1 by aberrant Wnt signaling maintains the undifferentiated state of colon cancer.
    Biochem Biophys Res Commun, 368(4): 923-9. [Abstract] [Full-text]
26. Validation of the lower gastrointestinal electronic referral protocol.
    Br J Surg, 95(4): 506-14. [Abstract] [Full-text]
27. Comparison of outcomes of ileal pouch-anal anastomosis for familial adenomatous polyposis with and without previous ileorectal anastomosis.
    Br J Surg, 95(4): 494-8. [Abstract] [Full-text]
28. Detoxification enzyme polymorphisms are not involved in duodenal adenomatosis in familial adenomatous polyposis.
    Br J Surg, 95(4): 499-505. [Abstract] [Full-text]
29. Liver resection-associated macrophage inflammatory protein-2 stimulates engraftment but not growth of colorectal metastasis at extrahepatic sites.
    J Surg Res, 145(2): 295-302. [Abstract] [Full-text]
30. Potential predictive markers of response to EGFR-targeted therapies in colorectal cancer.
    Crit Rev Oncol Hematol, 66(1): 21-30. [Abstract] [Full-text]
31. Adjuvant chemotherapy after resection in elderly Medicare and Medicaid patients with colon cancer.
    Arch Intern Med, 168(5): 521-9. [Abstract] [Full-text]
32. Enhanced tumour growth and impaired cellular antitumoural defense in hepatic colorectal carcinoma metastasis in rats after laparoscopy compared to open surgery.
    Ann Surg Oncol, 15(4): 1239-48. [Abstract] [Full-text]
33. Messenger RNA expression of vascular endothelial growth factor and its receptors in primary colorectal cancer and corresponding liver metastasis.
    Ann Surg Oncol, 15(4): 1232-8. [Abstract] [Full-text]
34. Patterns of failure and outcome in patients with carcinoma of the anal margin.
    Ann Surg Oncol, 15(4): 1092-8. [Abstract] [Full-text]
35. Perihepatic lymph node micrometastases impact outcome after partial hepatectomy for colorectal metastases.
    Ann Surg Oncol, 15(4): 1130-6. [Abstract] [Full-text]
36. Distributions of angiogenesis and lymphangiogenesis in gastrointestinal intramucosal tumors.
    Ann Surg Oncol, 15(4): 1117-23. [Abstract] [Full-text]
37. Quality of life among five-year survivors after treatment for very low rectal cancer with or without a permanent abdominal stoma.
    Ann Surg Oncol, 15(4): 1099-106. [Abstract] [Full-text]
38. Isolated chemotherapeutic perfusion of pelvis as neoadjuvant or palliative therapy for advanced cancer of the rectum.
    Ann Surg Oncol, 15(4): 1107-16. [Abstract] [Full-text]
39. Does a "one-stop" gynecology screening clinic for women in hereditary nonpolyposis colorectal cancer families have an impact on their psychological morbidity and perception of health?
    Int J Gynecol Cancer, 18(2): 279-84. [Abstract] [Full-text]
40. Further upregulation of beta-catenin/Tcf transcription is involved in the development of macroscopic tumors in the colon of ApcMin/+ mice.
    Carcinogenesis, 29(3): 666-72. [Abstract] [Full-text]
41. Polymorphisms within micro-RNA-binding sites and risk of sporadic colorectal cancer.
    Carcinogenesis, 29(3): 579-84. [Abstract] [Full-text]
42. Gab1 but not Grb2 mediates tumor progression in Met overexpressing colorectal cancer cells.
    Carcinogenesis, 29(3): 647-55. [Abstract] [Full-text]
43. Dacarbazine-Doxorubicin therapy ameliorated an extremely aggressive mesenteric desmoid tumor associated with familial adenomatous polyposis: report of a case.
    Jpn J Clin Oncol, 38(3): 222-6. [Abstract] [Full-text]
44. 1,1-bis(3'-indolyl)-1-(p-methoxyphenyl)methane activates Nur77-independent proapoptotic responses in colon cancer cells.
    Mol Carcinog, 47(4): 252-63. [Abstract] [Full-text]
45. Retinol decreases phosphatidylinositol 3-kinase activity in colon cancer cells.
    Mol Carcinog, 47(4): 264-74. [Abstract] [Full-text]
46. Silibinin inhibits colorectal cancer growth by inhibiting tumor cell proliferation and angiogenesis.
    Cancer Res, 68(6): 2043-50. [Abstract] [Full-text]
47. Diphenyl difluoroketone: a curcumin derivative with potent in vivo anticancer activity.
    Cancer Res, 68(6): 1962-9. [Abstract] [Full-text]
48. PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab.
    Cancer Res, 68(6): 1953-61. [Abstract] [Full-text]
49. Lipid bodies are reservoirs of cyclooxygenase-2 and sites of prostaglandin-E2 synthesis in colon cancer cells.
    Cancer Res, 68(6): 1732-40. [Abstract] [Full-text]
50. Liposomal formulation of 5-fluorocytosine in suicide gene therapy with cytosine deaminase--for colorectal cancer.
    Cancer Lett, 262(2): 164-72. [Abstract] [Full-text]
51. Preservation of the active lactone form of irinotecan using drug eluting beads for the treatment of colorectal cancer metastases.
    J Control Release, 127(1): 70-8. [Abstract] [Full-text]
52. Immunohistochemical expression of folate receptor alpha in colorectal carcinoma: patterns and biological significance.
    Hum Pathol, 39(4): 498-505. [Abstract] [Full-text]
53. Diagnostic efficacy of additional step-sections in colorectal biopsies originally diagnosed as normal.
    Hum Pathol, 39(4): 579-83. [Abstract] [Full-text]
54. Aurora kinase expression in colorectal adenocarcinoma: correlations with clinicopathological features, p16 expression, and telomerase activity.
    Hum Pathol, 39(4): 599-604. [Abstract] [Full-text]
55. Prostatic adenocarcinoma in colorectal biopsy: clinical and pathologic features.
    Hum Pathol, 39(4): 543-9. [Abstract] [Full-text]
56. Curative rectal cancer surgery in a low-volume hospital: a quality assessment.
    Eur J Surg Oncol, 34(4): 382-9. [Abstract] [Full-text]
57. Prognostic factors after preoperative irradiation and surgery for locally advanced rectal cancer.
    Eur J Surg Oncol, 34(4): 410-7. [Abstract] [Full-text]
58. The prognostic significance of extracapsular lymph node involvement in node positive patients with colonic cancer.
    Eur J Surg Oncol, 34(4): 390-6. [Abstract] [Full-text]
59. Biological characteristics and behaviour of putatively curatively resected colorectal liver metastases.
    Eur J Surg Oncol, 34(4): 439-44. [Abstract] [Full-text]
60. Major resection of hepatic colorectal liver metastases in elderly patients - an aggressive approach is justified.
    Eur J Surg Oncol, 34(4): 428-32. [Abstract] [Full-text]
61. A small mammal model of tumour implantation, dissemination and growth factor expression after partial hepatectomy.
    Eur J Surg Oncol, 34(4): 469-75. [Abstract] [Full-text]
62. Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials.
    J Clin Oncol, 26(9): 1443-51. [Abstract] [Full-text]
63. Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer.
    J Clin Oncol, 26(9): 1427-34. [Abstract] [Full-text]
64. Comparative lesion sequencing provides insights into tumor evolution.
    Proc Natl Acad Sci U S A, 105(11): 4283-8. [Abstract] [Full-text]
65. As tests evolve and costs of cancer care rise: reappraising stool-based screening for colorectal neoplasia.
    Aliment Pharmacol Ther, 27(8): 697-712. [Abstract] [Full-text]
66. Is there sufficient MDCT capacity to provide colorectal cancer screening with CT colonography for the U.S. population?
    AJR Am J Roentgenol, 190(4): 1044-9. [Abstract] [Full-text]
67. Women with undiagnosed colorectal adenocarcinomas presenting with ovarian metastases: clinicopathologic features and comparison with women having known colorectal adenocarcinomas and ovarian involvement.
    Int J Gynecol Pathol, 27(2): 182-90. [Abstract] [Full-text]
68. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial.
    Lancet, 371(9617): 1007-16. [Abstract] [Full-text]
69. Quality of CT colonography-related web sites for consumers.
    J Am Coll Radiol, 5(4): 593-7. [Abstract] [Full-text]
70. The methylator phenotype in microsatellite stable colorectal cancers is characterized by a distinct gene expression profile.
    J Pathol, 214(5): 594-602. [Abstract] [Full-text]
71. Specific imaging of VEGF-A expression with radiolabeled anti-VEGF monoclonal antibody.
    Int J Cancer, 122(10): 2310-4. [Abstract] [Full-text]
72. Designing antibodies for the inhibition of gastrin activity in tumoral cell lines.
    Int J Cancer, 122(10): 2351-9. [Abstract] [Full-text]
73. Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers.
    Int J Cancer, 122(10): 2255-9. [Abstract] [Full-text]
74. Anti-tumor activity of an anti-endoglin monoclonal antibody is enhanced in immunocompetent mice.
    Int J Cancer, 122(10): 2266-73. [Abstract] [Full-text]
75. Mitochondrial D310 mutations in colorectal adenomas: an early but not causative genetic event during colorectal carcinogenesis.
    Int J Cancer, 122(10): 2242-8. [Abstract] [Full-text]
76. Lack of interleukin-4 receptor alpha chain-dependent signalling promotes azoxymethane-induced colorectal aberrant crypt focus formation in Balb/c mice.
    J Pathol, 214(5): 603-9. [Abstract] [Full-text]
77. Differences in patient postoperative and long-term outcomes between obstructive and perforated colonic cancer.
    Am J Surg, 195(4): 427-32. [Abstract] [Full-text]
78. External validation of prognostic models among cancer patients undergoing emergency colorectal surgery.
    Am J Surg, 195(4): 439-41. [Abstract] [Full-text]
79. Systematic extended right posterior sectionectomy: a safe and effective alternative to right hepatectomy.
    Ann Surg, 247(4): 603-11. [Abstract] [Full-text]
80. IL-4/Stat6 activities correlate with apoptosis and metastasis in colon cancer cells.
    Biochem Biophys Res Commun, 369(2): 554-60. [Abstract] [Full-text]
81. Expression of cyclic guanosine monophosphate-dependent protein kinase in metastatic colon carcinoma cells blocks tumor angiogenesis.
    Cancer, 112(7): 1462-70. [Abstract] [Full-text]
82. A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity.
    Ann Oncol, 19(4): 734-8. [Abstract] [Full-text]
83. First-line single-agent cetuximab in patients with advanced colorectal cancer.
    Ann Oncol, 19(4): 711-6. [Abstract] [Full-text]
84. EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients.
    Ann Oncol, 19(4): 717-23. [Abstract] [Full-text]
85. Should a colon cancer screening decision aid include the option of no testing? A comparative trial of two decision aids.
    BMC Med Inform Decis Mak, 8: 10. [Abstract] [Full-text]
86. Genome-wide pattern of TCF7L2/TCF4 chromatin occupancy in colorectal cancer cells.
    Mol Cell Biol, 28(8): 2732-44. [Abstract] [Full-text]
87. Decreased CHK protein levels are associated with Src activation in colon cancer cells.
    Oncogene, 27(14): 2027-34. [Abstract] [Full-text]
88. The N-methyl-D-aspartate receptor type 2A is frequently methylated in human colorectal carcinoma and suppresses cell growth.
    Oncogene, 27(14): 2045-54. [Abstract] [Full-text]
89. Flat adenoma-carcinoma sequence with high-malignancy potential as demonstrated by CD10 and beta-catenin expression: a different pathway from the polypoid adenoma-carcinoma sequence.
    Histopathology, 52(5): 569-77. [Abstract] [Full-text]
90. The in vivo rate of somatic adenomatous polyposis coli mutation.
    Am J Pathol, 172(4): 1062-8. [Abstract] [Full-text]
91. Proteasome inhibition potentiates the cytotoxic effects of hyperthermia in HT-29 colon cancer cells through inhibition of heat shock protein 27.
    Oncology, 73(1): 98-103. [Abstract] [Full-text]
92. Gene expression of fructosamine 3 kinase in patients with colorectal cancer.
    Oncology, 73(1): 72-5. [Abstract] [Full-text]
93. Colorectal cancer or colon and rectal cancer? Clinicopathological comparison between colonic and rectal carcinomas.
    Oncology, 73(1): 52-7. [Abstract] [Full-text]
94. A randomized phase II trial of pemetrexed plus irinotecan (ALIRI) versus leucovorin-modulated 5-FU plus irinotecan (FOLFIRI) in first-line treatment of locally advanced or metastatic colorectal cancer.
    Oncology, 73(1): 9-20. [Abstract] [Full-text]
95. Raf kinase inhibitor protein: mechanism of loss of expression and association with genomic instability.
    J Clin Pathol, 61(4): 524-9. [Abstract] [Full-text]
96. Oestrogen and the colon: potential mechanisms for cancer prevention.
    Lancet Oncol, 9(4): 385-91. [Abstract] [Full-text]
97. Colorectal carcinoma with dome-like phenotype: an under-recognised subset of colorectal carcinoma?
    J Clin Pathol, 61(4): 482-6. [Abstract] [Full-text]
98. Complete pathologic response after preoperative chemotherapy for colorectal liver metastases: myth or reality?
    J Clin Oncol, 26(10): 1635-41. [Abstract] [Full-text]
99. Clinical and endorectal ultrasound staging of circumferential rectal cancers.
    J Med Imaging Radiat Oncol, 52(2): 161-3. [Abstract] [Full-text]
100. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.
     J Clin Oncol, 26(10): 1626-34. [Abstract] [Full-text]

© 2004-2008 Colorectal Cancer Research Today. All Rights Reserved.